Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Brandon Couillard
Period: Reporting periods mapped to calendar 2024 Q4 – 2026 Q1 (6 quarters).
- Questions
- 25on tracked calls
- Challenge rate
- 0%none of 25 questions
- Companies
- 5questioned at least once
- Reporting periods
- 6with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 25 of 25 questions from 5 companies
AAgilent Technologies10 questions · 5 reporting periods · 0 of 10 challenging
Calendar 2026 Q1
The 6% growth in China, was that all stimulus related and would be helpful if you can just touch on a couple of the end markets there.
Show response
Padraig described China better than expected. Won ~30% of small GACC stimulus. Over-indexed to applied markets, under-indexed to DX and pharma. Larger SAMR stimulus excluded from guide as upside. Optimistic about China with 15th 5-year plan alignment.
I think Simon said Europe was pretty solid. So just curious where you're seeing the weakness visits all in the Americas?
Show response
Adam confirmed A&G softness primarily in Americas. NIH budget flat to slightly up, 15% overhead cap blocked. Simon clarified Europe comment was forward-looking, expects more stability there with cautious optimism.
Calendar 2025 Q4
Do you expect to see a halo benefit as the instrument cycle continues to escalate next year? Or are you just sort of being conservative here
Show response
Padraig noted 6% Q4 growth (8% ex China) with healthy installed base growth and ramping attach rates. Angelica added Alturo column adoption, remote plus services, open lab CDS demand, and automation growth as FY2026 drivers. Comprehensive.
What was net pricing in the fourth quarter? And I think you talked about 100 basis points in fiscal '26, but that there could be upside to that.
Show response
Rodney confirmed Q4 pricing reached 150bps, above the 100bps run rate. FY2026 guiding well above 100bps with upside potential. Brief but precise.
Calendar 2025 Q2
Bob, you took down the operating cash flow guide for the year. Is that driven by tariffs and maybe inventory builds?
Show response
Bob confirmed inventory build and working capital as drivers of OCF reduction. Currency ~1-2pp EPS impact for full year. Direct.
Are you less likely to consider a larger deal right now given the macro, tariffs, interest rate volatility? Or are you seeing more attractive valuations for assets?
Show response
Padraig emphasized strategic discipline over short-term macro noise, noted lower valuations, and stated M&A will be a bigger part of the story. Direct.
Calendar 2025 Q1
it'd be great if you could get an update just on the pathology and genomics pieces and how those performed in the first quarter.
Show response
Simon gave balanced genomics update, NIH headwinds offset by Magnus NGS prep traction. Pathology flat but steady trajectory. Bob added diagnostics grew 7% overall.
Bob, can you just help us understand what's going on with gross margins, down over 130 basis points in the first quarter? Was that in line with your expectations?
Show response
Bob attributed to mix (China stimulus), currency (20-30bps), and noted pricing was trending higher than expected. Direct with improvement outlook.
Calendar 2024 Q4
how much of the CapEx is in Nexter is tied to the train B and build out for NASD, we expect those to come online, and what does maintenance CapEx look like?
Show response
Bob provided clear CapEx breakdown: ~$225M for NASD, maintenance CapEx at 2.5-3% of sales. Very direct and quantified.
can you remind us, you know, when the Infinity 2 I think it's the 1290 system rolled out. And what's the is there an ASP premium?
Show response
Padraig declined to discuss ASP specifics but emphasized broad installed base opportunity beyond just Infinity 2 to Infinity 3 upgrades. Bob added pricing has held up.
MTDMettler Toledo5 questions · 3 reporting periods · 0 of 5 challenging
Calendar 2026 Q1
Are there any pockets of lab that are doing better, like bioprocess there
Show response
Shawn gave China up 4%, industrial high single-digit and lab down slightly; Patrick added biopharma strong, small-molecule chem soft.
Calendar 2025 Q3
it's atypical for Mettler to do one deal, much less a handful of them. I'd love if you could just kind of elaborate on how this came about
Show response
Patrick explained multiple small deals were long in preparation. Included North American distribution partners, new service capabilities, and Genie Vortex mixers expanding life science equipment portfolio. Revenue contribution less than 1% in Q3, about 1% through H1 2026.
did you give the lab -- the China lab growth in the quarter? And what is embedded for '25 for China and those 2 segments specifically
Show response
Shawn confirmed China lab was up low single digit in Q3 and expects low single digit for next year as well.
Calendar 2025 Q1
When you're talking about seeing some orders being delayed, some pushouts for projects, is that isolated to core industrial? Was that a China-specific comment or more global
Show response
Shawn clarified hesitation mainly in China Q2. Western markets still optimistic with good customer activity. China customers mostly serving local market, not exporters.
it doesn't look like your free cash flow guide actually changed at all. How do you just, I guess, approach managing working capital in this environment
Show response
Shawn noted strong Q1 free cash flow (up 17% per share ex-bonus timing) and ongoing optimization of working capital and other line items.
WATWaters Corporation5 questions · 3 reporting periods · 0 of 5 challenging
Calendar 2025 Q3
second quarter in a row, China has been up double digits, a lot better than peers. Do you think that's unique to Waters in your portfolio
Show response
Management attributed China outperformance to localized portfolio, expanded distribution and CDMO strength; modeling high single-digit Q4.
Calendar 2025 Q1
Did the PFAS business thing to really accelerate quite a bit here in the quarter, clocking a new high up 90%. Is there any timing benefit in that growth rate
Show response
Management saw no pull-forward in PFAS growth, with strong ongoing funnel driven by regulatory expansion.
What's your appetite for another $1 billion-plus deal or maybe even something more transformative
Show response
Management signaled active M&A pipeline with more reasonable valuations, with Wyatt as the model for strategic fit.
Calendar 2024 Q4
your PFAS market sizing continues to walk up. Now, you're talking about a $400 million opportunity, prior it was kind of $300 million to $350 million
Show response
Management explained market expansion driven by new application areas in food, materials and consumer products beyond water testing.
I think you talked about instrument growth this year 4%, 4.5%. Just curious how that compares between the LC, mass spec and light scattering
Show response
Management broke down expected 2025 instrument growth at roughly mid-single digits across all segments.
TECHBio-Techne4 questions · 2 reporting periods · 0 of 4 challenging
Calendar 2025 Q4
You're sticking with the 100 basis points for the full year. But you previously talked about maybe exiting up 200 bps year-over-year
Show response
Jim explained sequential margin expansion driven half by gross margin improvement as negative mix unwinds and half by higher revenue leverage. Q3 tougher comp on operating margin, Q4 easier, targeting 100bp improvement for the second half.
question on operating cash flow down pretty meaningfully. In the first half
Show response
Jim cited two drivers: larger Q1 incentive comp payout versus low prior-year payout, and tax payment timing that will gradually unwind through the fiscal year. Q2 cash flow was strong and on par with prior year.
Calendar 2025 Q2
How would that kind of break down between consumables and instruments? And was there any stimulus benefit in the period?
Show response
Kim confirmed some stimulus-related instrument shipments and relatively similar consumable/instrument mix. Jim added reagent growth was more consistent with the flat-to-modest market growth thesis, with instruments benefiting from tariff pull-forward.
Does that assume an accelerating top line outlook? And if you could just touch on kind of what's embedded for net pricing and any tariff headwinds
Show response
Jim clarified the 200bp Q4 target comes from three factors: ExoDx rolling off, ongoing productivity gains, and seasonal revenue uplift in back half. Not dependent on accelerating top line.
RVTYRevvity1 question · 1 reporting period · 0 of 1 challenging
Calendar 2025 Q4
can you give us a little more color on the levers to improvement there and kind of where you're seeing free cash flow shake out for '26?
Show response
Max attributed ~90% FCF conversion to working capital initiatives, higher recurring revenue mix, and company-wide cash flow incentives. LRP target of 85%+ expected for FY26.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| A Agilent Technologies | 10 | 0%none of 10 questions |
| MTD Mettler Toledo | 5 | 0%none of 5 questions |
| WAT Waters Corporation | 5 | 0%none of 5 questions |
| TECH Bio-Techne | 4 | 0%none of 4 questions |
| RVTY Revvity | 1 | —Rate withheld: fewer than 3 questions |
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2024 Q4 | 4 | 0%none of 4 questions | 2 |
| 2025 Q1 | 6 | 0%none of 6 questions | 3 |
| 2025 Q2 | 4 | 0%none of 4 questions | 2 |
| 2025 Q3 | 3 | 0%none of 3 questions | 2 |
| 2025 Q4 | 5 | 0%none of 5 questions | 3 |
| 2026 Q1 | 3 | 0%none of 3 questions | 2 |
- 2024 Q44 questions · challenge rate 0% (none of 4 questions) · 2 companies
- 2025 Q16 questions · challenge rate 0% (none of 6 questions) · 3 companies
- 2025 Q24 questions · challenge rate 0% (none of 4 questions) · 2 companies
- 2025 Q33 questions · challenge rate 0% (none of 3 questions) · 2 companies
- 2025 Q45 questions · challenge rate 0% (none of 5 questions) · 3 companies
- 2026 Q13 questions · challenge rate 0% (none of 3 questions) · 2 companies
Topics
Topics tagged on this analyst’s questions.
- Demand12
- Capital Allocation7
- Margin5
- Geographic Expansion4
- M&A3
- Cost Pressure2
- Regulation Policy2
- Revenue Growth2
- Pricing2
- Macroeconomic2
Show all 15 topics
- Competitive Dynamics2
- Fx2
- Product Launch2
- Guidance Reliability1
- Capex Investment1